Island Pharmaceuticals finalized its acquisition of the antiviral asset Galidesivir from BioCryst Pharmaceuticals, Inc., thereby significantly expanding its pipeline. It engaged with the U.S. Food and Drug Administration via a Type C meeting request under its open IND to explore approval under the “Animal Rule” pathway with feedback expected by 12 November 2025 (US time). The historical data included very promising non-human primate survival rates (94% survival in Marburg-infected primates compared to 0% in placebo).
